Mutant Sodium Channel for Tumor Therapy
70598 mt200933a.pdf (4.256Mb)
Access StatusFull text of the requested work is not available in DASH at this time ("restricted access"). For more information on restricted deposits, see our FAQ.
Tannous, Bakhos A.
Christensen, Adam P.
Perry, Katherine F.
Jacobs, Andreas H.
Corey, David P.
Breakefield, Xandra O.
MetadataShow full item record
CitationTannous, Bakhos A, Adam P Christensen, Lisa Pike, Thomas Wurdinger, Katherine F Perry, Okay Saydam, Andreas H Jacobs, et al. 2009. “Mutant Sodium Channel for Tumor Therapy.” Molecular Therapy 17 (5): 810–19. https://doi.org/10.1038/mt.2009.33.
AbstractViral vectors have been used to deliver a wide range of therapeutic genes to tumors. In this study, a novel tumor therapy was achieved by the delivery of a mammalian brain sodium channel, ASIC2a, carrying a mutation that renders it constitutively open. This channel was delivered to tumor cells using a herpes simplex virus-1/Epstein-Barr virus (HSV/EBV) hybrid amplicon vector in which gene expression was controlled by a tetracycline regulatory system (tet-on) with silencer elements. Upon infection and doxycycline induction of mutant channel expression in tumor cells, the open channel led to amiloride-sensitive sodium influx as assessed by patch clamp recording and sodium imaging in culture. Within hours, tumor cells swelled and died. In addition to cells expressing the mutant channel, adjacent, noninfected cells connected by gap junctions also died. Intratumoral injection of HSV/EBV amplicon vector encoding the mutant sodium channel and systemic administration of doxycycline led to regression of subcutaneous tumors in nude mice as assessed by in vivo bioluminescence imaging. The advantage of this direct mode of tumor therapy is that all types of tumor cells become susceptible and death is rapid with no time for the tumor cells to become resistant.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:41384283
- HMS Scholarly Articles